Vertex Pharma (VRTX) Says Lung Function Improvement from VX-809 Phase 2 Was Overstated in Last Release
Go back to Vertex Pharma (VRTX) Says Lung Function Improvement from VX-809 Phase 2 Was Overstated in Last Release| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 548.05 +7.79 (1.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $540.26 | 52 Week High | $134.71 | |||
| Open | $545.10 | 52 Week Low | $73.31 | |||
| Day High | $555.32 | P/E | N/A | |||
| Day Low | $540.70 | EPS | $-1.98 | |||
| Volume | 1,074,988 | |||||
